Today's Information

Provided by: LUMOSA THERAPEUTICS CO., LTD.
SEQ_NO 1 Date of announcement 2022/05/24 Time of announcement 17:34:17
Subject 
 LUMOSA Shareholders' Meeting approved to release
the company's directors from non-competition restrictions
Date of events 2022/05/24 To which item it meets paragraph 21
Statement 
1.Date of the shareholders' meeting resolution:2022/05/24
2.Name and title of the managerial officer with permission
 to engage in competitive conduct:
Director：Center Laboratories, Inc.
Director：Jung Chin Lin Representative of Center Laboratories, Inc.
Director：Wann Lai Cheng Representative of Center Laboratories, Inc.
Director：Su-Chi Wang Representative of BioEngine Technology Development Inc.
Director：De-Fu Hsieh Representative of 順晟藥品有限公司
Independent Director：Chih Yung Chin
3.Items of competitive conduct in which the officer is
permitted to engage:
The director's concurrent position in other company whose business is partly
the same or similar with the Company.
4.Period of permission to engage in the competitive conduct:
During the term of being a director of the company.
5.Circumstances of the resolution (please describe the
results of voting in accordance with Article 209 of the
Company Act):
Voting results: 94,076,082 voting rights in favor, accounting for 99.91% of
the 94,155,642 voting rights of shareholders present at the time of the poll,
and the lifting of the company's director's prohibition on competition.
6.If the permitted competitive conduct belongs to the
operator of a mainland China enterprise, the name and
title of the directors (if it is not the operator of
a mainland China enterprise, please enter "N/A" below):
(1)Director：Jung Chin Lin Representative of Center Laboratories, Inc.
(2)Director：Su-Chi Wang Representative of BioEngine Technology Development
             Inc.
7.Company name of the mainland China enterprise and the
officer's position in the enterprise:
(1)Director：Jung Chin Lin Representative of Center Laboratories, Inc.
   Director, Shanghai Bao Pharmaceutical Co., Ltd.
   Director, Centergene Pharmaceuticals Co., Ltd.
(2)Director：Su-Chi Wang Representative of BioEngine Technology Development
             Inc.
   Director, Bioflag Co., Ltd. (Huai'an)
   Director, Ausnutria Dairy (China) Co., Ltd.
   Director, Hyproca Bio-science Co.,Ltd.
   Director, Hyproca Nutrition Co. Ltd.
8.Address of the mainland China enterprise:
(1)Director：Jung Chin Lin Representative of Center Laboratories, Inc.
   Shanghai Bao Pharmaceutical Co., Ltd.：50 Luoxin Road, Baoshan District,
   Shanghai
   Centergene Pharmaceuticals Co., Ltd.：Unit 301B, C13 building, bio nano
   Park,218 Xinghu street, Suzhou Industrial Park
(2)Director：Su-Chi Wang Representative of BioEngine Technology Development
             Inc.
   Bioflag Co., Ltd. (Huai'an): No.2, Jingyi Road, Huai'an E.D.A.
   Ausnutria Dairy (China) Co., Ltd.: Floor 8, Xindaxin Building A, No.168,
   Huangxing Middle Road, Changsha, Hunan, China
   Hyproca Bio-science Co.,Ltd.: No.2, Wangwang East Road, Wangcheng District
   Economic and Technology Development Zone, Changsha, Hunan, China
   Hyproca Nutrition Co. Ltd.：Floor 21, Block B, Zuopin, No.1, No.399, Bayi
   Road, Furong District, Changsha, Hunan, China
9.Operations of the mainland China enterprise:
(1)Director：Jung Chin Lin Representative of Center Laboratories, Inc.
   Shanghai Bao Pharmaceutical Co., Ltd.：Protein drug development
   Centergene Pharmaceuticals Co., Ltd.：Research and development
   of biopharmaceutical technology
(2)Director：Su-Chi Wang Representative of BioEngine Technology Development
             Inc.
   Bioflag Co., Ltd. (Huai'an): Nutritional supplements development and
   production
   Ausnutria Dairy (China) Co., Ltd.: Production, marketing and distribution
   of dairy and related products in Mainland China
   Hyproca Bio-science Co.,Ltd.: Marketing and distribution of dairy products
   in Mainland China
   Hyproca Nutrition Co. Ltd.: Marketing and distribution of goat milk
   nutrition products in Mainland China
10.Impact on the company's finance and business:None
11.If the directors have invested in the mainland China
enterprise, the monetary amount of the investment and
their shareholding ratio:None
12.Any other matters that need to be specified:None

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Lumosa Therapeutics Co. Ltd. published this content on 24 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 May 2022 09:47:09 UTC.